Chelsea Kellams, APRN
Adult Health · New Albany, INNPI 1063996254
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 367 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AstraZeneca at 27.2% of the total. Among adult health clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 367 payments — averaging $20.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- AbbVie$2K
- Novo Nordisk$714
- GSK$459
- Pfizer$406
- Lilly USA, LLC$332
- plus $2K from 27 others
What the payments were for
- Food & beverage$7,48199%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $2,064 |
| AbbVie | 95 | $1,575 |
| Novo Nordisk | 39 | $714 |
| GSK | 27 | $459 |
| Pfizer | 31 | $406 |
| Lilly USA, LLC | 23 | $332 |
| Astellas Pharma US Inc | 8 | $220 |
| Exact Sciences | 10 | $190 |
| Otsuka America Pharmaceutical, Inc. | 9 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $162 |
| Johnson & Johnson | 3 | $155 |
| Axsome Therapeutics, Inc. | 8 | $142 |
| Biotissue Holdings Inc. | 1 | $110 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $108 |
| Mylan Specialty L.p. | 5 | $99 |
| Idorsia Pharmaceuticals US Inc | 4 | $83 |
| Boehringer Ingelheim | 4 | $81 |
| Dexcom, Inc. | 2 | $56 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $49 |
| Bayer | 3 | $47 |
| Edwards Lifesciences | 1 | $42 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Medtronic | 2 | $36 |
| Pulmonx Corporation | 2 | $34 |
| Viatris Specialty LLC | 2 | $32 |
| Verona Pharma, Inc. | 2 | $32 |
| Novartis | 1 | $32 |
| Vertex | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Tris Pharma Inc | 1 | $18 |
| Merck | 1 | $15 |
| Abbott | 1 | $15 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,581 in reported general payments places this provider in the 95th percentile of 391 adult health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 11 | $28,962 |
| JardianceEmpagliflozin | 13 | $20,666 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $14,024 |
| GemtesaVibegron | 12 | $10,106 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,067 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $1,983 |
| Ropinirole ErRopinirole Hcl | 11 | $882 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $868 |
| Levothyroxine Sodium | 73 | $779 |
| Atorvastatin Calcium | 86 | $596 |
| Cyclobenzaprine Hcl | 29 | $512 |
| Duloxetine Hcl | 14 | $489 |
| Lisinopril | 79 | $476 |
| FenofibrateFenofibrate Nanocrystallized | 22 | $474 |
| Montelukast Sodium | 39 | $348 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus | $714 | $28,96211 claims |
| Boehringer IngelheimJardiance | $81 | $20,66613 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $459 | $18,09130 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $24 | $10,10612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 391 adult health providers in Indiana.
Other adult health in New Albany
- Nicole MooreNew Albany$8K
- Kimberly RobertsonNew Albany$5K
- Lauren EurtonNew Albany$3K
- Jennifer BerryIndianapolis$50K
- Tajuana DavisZionsville$31K
- Patricia Damron-RobinsonMerrillville$20K
- Terry RidgeCarmel$20K
- Kristine StarcevichMerrillville$19K
- Jolyn Holliday VezaGreenfield$17K
- Anna MatulewiczMishawaka$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.